Webcast - ASH®20 Annual Meeting Review

Important Information

This educational activity features recorded lectures and discussions from our live-virtual educational activity - "ASH2020 Annual Meeting Review" held on December 12, 2020 & December 19, 2020. If you participated in that educational activity, you may watch these videos and complete all other course objects. However, you will not be eligible to claim Continuing Education credits for this activity. 

If you did not participate in our ASH2020 Annual Meeting Review on December 12, 2020 and/or December 19, 2020, you may be eligible for continuing education credits if you participate in this educational activity and complete all required course objects. Please  claim continuing education credits only to the extent of your participation.

Commercial Support Disclosure:

The 2020 Updates on Hematology and Hematologic Malignancies –Highlights from the 62nd ASH Annual Meeting & Exposition was supported with independent medical education grants from Bristol Myers Squibb, Dova Pharmaceuticals, and Jazz Pharmaceuticals.

REGISTRATION FEES: 

Registration is free for healthcare providers who are NOT employees of ACCME defined ineligible companies.

If you are a healthcare provider involved in patient care and are not an employee of an ineligible company, please proceed to registration and select "non-industry learner" and your fee will reset to $0.00.

An ineligible company is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients with the exception of hospitals and facilities that provide direct care to patients. If you are an employee of an ineligible company, please select "industry representative" and pay the industry registration fee when registering for this course.

Any industry representative enrolled in this educational activity without a payment of registration fee will incur additional penalty equivalent to the amount of registration fee. 

Target Audience

  • Oncologists
  • Residents/Fellows
  • NPs/PAs
  • Pharmacists
  • Nurses

Learning Objectives

At the conclusion of the activity, participants will be able to:

  • Discuss new and updated treatment options for patients with blood disorders and hematologic malignancies 
  • Identify side effects, indications, and contra-indications of various therapies used to diagnose and treat blood disorders and hematologic malignancies, and explain how to effectively manage those side-effects
  • Summarize diagnostic and treatment-related data relevant to multidisciplinary care
  • Review data presented at the 62nd ASH Annual Meeting (2020) and discuss their application in clinical settings
Course summary
Available credit: 
  • 5.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 0.00 Attendance
  • 5.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.50 Contact Hours.
Course opens: 
04/06/2020
Course expires: 
12/18/2021
Cost:
$0.00

December 12, 2020 Material

- Lymphoma

- 55 Minute Recording - Lymphoma – Dr. John Leonard , Weill Cornell Medicine

      

-  Myeloproliferative Neoplasms

          - 20 Minute Recording - Chronic Myeloid Leukemia – Dr. Jerry Radich – Fred Hutch

          - 25 Minute Recording - Non-CML Myeloproliferative Neoplasms – Dr. Vivian Oehler – Seattle Cancer Care Alliance

          - 15 Minute Recording - Rapid-fire Q & A – Dr. Srinivas Tantravahi – University of Utah

 

- Multiple Myeloma

          - 30 Minute Recording - Lecture – Dr. Shaji Kumar  Mayo School of Medicine

         - 15 Minute Recording - Rapid-fire Q & A –Dr. Andrew Cowan – University of Washington

 

December 19, 2020 Material 

- Leukemia

- 50 Minute Recording - Acute Leukemia – Dr. Elihu Estey – University of Washington

- 35 Minute Recording - Chronic Lymphocytic Leukemia – Dr. Deborah Stephens – University of Utah

         

 - Bleeding and Clotting Disorders

- 40 Minute Recording - Hemophilia – Dr. Doris Quon – Orthopedic Hemophilia Treatment Center

- 20 Minute Recording - Clotting Disorders – Dr. George Rodgers – University of Utah

- 25 Minute Recording - TTP/aHUS – Dr. Ming Lim – University of Utah

 

image

Shaji Kumar, MD

Professor of Medicine

Mayo School of Medicine

Learn More

image

Deborah Stephens, DO

Assistant Professor of Medicine 

Huntsman Cancer Institute

Learn More

image

Elihu “Eli” Estey, MD

Professor of Medicine

University of Washington & Fred Hutch

Learn More

image

David Aboulafia, MD 

Section Head - Department of Hematology/Oncolog

Virginia Mason

Learn More

image

Andrew J. Cowan, MD

Assistant Professor of Medicine

Seattle Cancer Care Alliance

Learn More

image

Vivian G. Oehler, MD

Associate Professor of Medicine 

Fred Hutch & University of Washington 

Learn More

image

George Rodgers, MD, PhD

Professor of Medicine

University of Utah 

Learn More

image

Doris Quon, MD, PhD

Medical Director, Orthopaedic Hemophelia Treatment Center

UCLA Health

Learn More

image

John P. Leonard, MD

Professor of Medicine

Weill Cornell Medicine

Learn More

image

Srinivas Tantravahi, MBBS, MRCP

Assistant Professor of Medicine

University of Utah

Learn More

image

Ming Lim, MBBCh, MS

Assistant Professor

University of Utah  

Learn More

image

Jerald Radich, MD

 

Professor of Medicine

Fred Hutch 

Learn More

Disclosure of Conflict of Interest

The Binaytara Foundation collects disclosure information from all faculty and organizing committee members involved in planning, implementation, and evaluation of our continuing medical education activities. All conflict has been identified and mitigated for everyone in control of the contents of this activity before their participation in this educational activity.

No member of the activity planning committee, faculty members, or anyone in control of the content has any relevant financial relationship with an ACCME defined ineligible company with the exception of:

Deborah Stephens, DO

Disclosures: Consulting/Advisory Board: Jannsen, Pharmacyclics, Karyopharm, Innate Pharma, Epizyme; Reseaarch/Grant Support: Acerta, Juno, Gilead, Vernstem, Arqule, Mingsight

Discussion of Off label/Investigational/Unapproved products: Yes. Faculty will disclose during presentation when discussing such products.

 

Doris Quon, MD

Disclosures: Consulting/Advisory Board: Bayer, Biomarin, Genentech, NovoNordisk, UniQure; Speaker Bureau: Bioverativ-Sanofi, Shire/Takeda, Genentech, NovoNordisk

Discussion of Off label/Investigational/Unapproved products: Yes. Faculty will disclose during presentation when discussing such products.

 

George Rodgers, MD

Disclosures: Consultant: Dova, Sanofi

Discussion of Off label/Investigational/Unapproved products: None.

 

Ming Lim, MBBCh

Disclosures: Consultant: Sanofi, Argenx

Discussion of Off label/Investigational/Unapproved products: None.

 

John Leonard, MD

Disclosures:Consultant: Sotro Biopharma, Miley Meds, AstraZeneca, Epizyme, BMS/Celgene, MEI pharma, Bayer, Gilead/KITE, Karyo Pharma, Genmab, Genentech/Roche, AbbVie, Incyte

Discussion of Off label/Investigational/Unapproved products: Yes. Faculty will disclose during presentation when discussing such products.

 

Jerald Radich, MD

Disclosures:Consultant: Novartis, Amgen; Research/Grant Support: Genentech, Novartis, Amgen

Discussion of Off label/Investigational/Unapproved products: No.

 

Vivian Oehler, MD

Disclosures: Consultant/Advisory Board: Takeda & BMS; Research/Grant Support: Pfizer

Discussion of Off label/Investigational/Unapproved products: None.

 

Shaji Kumar, MD

Disclosures: Research/Grant Support: Celgene, Takeda, Jassen, BMS, Sanofi, KITE, Merck, Medimmune, Novartis, Roche-Genentech, Amgen, Tenebio; Consultant/Advisory Board: Celgene, Takeda, Jannsen, KITE, Merck, Abbvie, Medimmune, Genentech, Amgen, Oncopeptides, Beigene, Anentegen, Gilead

Discussion of Off label/Investigational/Unapproved products: Yes. Faculty will disclose during presentation when discussing such products.

 

Andrew Cowan, MD

Disclosures: Abbvie, Jannsen, BMS, Cellectar, Sanofi-Aventis, Nektar; Consulting/Advisor: Jannsen, Cellectar, Sanofi-Aventis

Discussion of Off label/Investigational/Unapproved products: Yes. Faculty will disclose during presentation when discussing such products.

 

 

 

 

 

 

 

 

 

Important Information about Claiming Continuing education credits for this activity:

If you participated in our live webinar on 12/12/2020 - 12/19/2020 and claimed Continuing Education credits for that activity, you do not qualify for CE/CME credits  for your participation in this enduring activity. This is a recorded content from those live webinars on 12/12/21 & 12/19/21. 


The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.

The Binaytara Foundation designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 5.5 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

Nursing Contact Hours: Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.5 Contact Hours.

Available Credit

  • 5.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 0.00 Attendance
  • 5.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.50 Contact Hours.

Price

Cost:
$0.00
Please login or register to take this course.

Registration Fees:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0. 

Healthcare providers ($0.00)

Industry employees ($200 + 3% Credit card fee) 

 

If you are a healthcare provider involved in patient care and you are not employed by the Industry, please register for the course here

If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid registrations will be invoiced $350 per participant. Sign up for this activity as an industry representative here. If you paid to join the live meeting and wish to register for this enduring material please contact us and we will register you for free.

 

Cancellation Policy

You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, watching the recorded content, and completion of pre & post tests as well as course evaluations.

 

Refund Policy 

This activity is free for all healthcare providers who are not employees of an ineligible entity.

No refunds will be issued if you have started watching the recorded content.